299 related articles for article (PubMed ID: 35485219)
1. Bispecific antibodies for immune cell retargeting against cancer.
Chen RP; Shinoda K; Rampuria P; Jin F; Bartholomew T; Zhao C; Yang F; Chaparro-Riggers J
Expert Opin Biol Ther; 2022 Aug; 22(8):965-982. PubMed ID: 35485219
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies in cancer immunotherapy.
Rader C
Curr Opin Biotechnol; 2020 Oct; 65():9-16. PubMed ID: 31841859
[TBL] [Abstract][Full Text] [Related]
3. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
4. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
5. Bispecific and multispecific antibodies in oncology: opportunities and challenges.
Goebeler ME; Stuhler G; Bargou R
Nat Rev Clin Oncol; 2024 Jul; 21(7):539-560. PubMed ID: 38822215
[TBL] [Abstract][Full Text] [Related]
6. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
7. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Wu Z; Cheung NV
Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
[TBL] [Abstract][Full Text] [Related]
8. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.
Ellerman D
Methods; 2019 Feb; 154():102-117. PubMed ID: 30395966
[TBL] [Abstract][Full Text] [Related]
9. Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents.
Kopp A; Guan J; Johnston C; Vance S; Legg J; Galson-Holt L; Thurber GM
AAPS J; 2024 Jun; 26(4):68. PubMed ID: 38862748
[TBL] [Abstract][Full Text] [Related]
10. Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development.
Chen TT
Expert Opin Biol Ther; 2022 Aug; 22(8):955-963. PubMed ID: 35857922
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies for the treatment of breast cancer.
Dillon PM; Tushir-Singh J; Lum LG
Expert Opin Biol Ther; 2022 Aug; 22(8):1017-1027. PubMed ID: 33896311
[TBL] [Abstract][Full Text] [Related]
12. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
Guy DG; Uy GL
Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
[TBL] [Abstract][Full Text] [Related]
14. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
15. Alternative molecular formats and therapeutic applications for bispecific antibodies.
Spiess C; Zhai Q; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
[TBL] [Abstract][Full Text] [Related]
16. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B; DomÃnguez-Alonso C; Alvarez-Vallina L
Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
[TBL] [Abstract][Full Text] [Related]
18. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
Yang F; Wen W; Qin W
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]